AHA 2026: Major Heart Trials in Chicago — Lp(a), Obesity Drugs and AI in Focus
Written by AI from radcliffecardiology.com's report. Not checked by a person.
The American Heart Association's Scientific Sessions 2026 is under way at McCormick Place in Chicago from 6–9 November, with 23 late-breaking trial presentations scheduled across six sessions from 7–9 November, covering new cholesterol-lowering drugs, obesity cardiovascular outcomes, heart-valve surgery and AI diagnostics.
The American Heart Association Scientific Sessions 2026 is taking place from 6–9 November at McCormick Place Convention Center in Chicago, Illinois. The meeting features 23 late-breaking clinical trial presentations across six dedicated sessions running from 7 to 9 November. Among the headline studies is Lp(a)HORIZON, which evaluates pelacarsen for reducing cardiovascular outcomes in patients with elevated lipoprotein(a). The ZEUS trial examines ziltivekimab in patients with cardiovascular disease, chronic kidney disease and systemic inflammation. SYNCHRONIZE-CVOT assesses cardiovascular outcomes with survodutide in patients with obesity. The PROGRESS trial compares transcatheter aortic valve replacement against clinical surveillance in patients with moderate — rather than severe — aortic stenosis, potentially expanding who qualifies for the procedure. The programme also includes sessions on stroke therapies, blood-pressure management, arrhythmia care, statin use in older adults, CRISPR-based gene editing for lipid disorders and AI-assisted cardiac screening using smartwatches and echocardiography. Independent editorial coverage of the meeting, including trial summaries, expert interviews and clinical analysis, is being provided by Radcliffe Cardiology. The meeting continues through 9 November.
